Form 4 for BLTE BELITE BIO, INC
Accepted 2026-08-14 06:10:04 ET · period of report 2026-08-12 · accession 0001193125-26-350217 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-14 06:10 | 2026-08-12 | BLTE | Lin Yu-Hsin | CEO, Dir | S - Sale | $180.35 | -365 | 170.6K | -0.2% | -$65.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American depositary share | 2026-08-12 | S | D | 142 | $180.00 | 170,792 | D | — | — | (F1) Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. (F2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025. |
| 2 | Common | American depositary share | 2026-08-12 | S | D | 223 | $180.57 | 170,569 | D | — | — | (F1) Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. (F2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025. |